Podcast appearances and mentions of raj kumar

June 8, 2026 ~ Political strategist Roshini Rajkumar reacts to Hunter Biden mocking his past scandals on X. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Raj, Ashwin, and Eddie sit down with Dr. Vincent Rajkumar — Professor of Medicine at Mayo Clinic and Chair of the ECOG Myeloma Committee — for a clinically focused conversation on newly diagnosed multiple myeloma. Topics span baseline workup, risk stratification, induction selection, transplant timing, MRD-directed decision-making, and maintenance strategy. The episode closes with a discussion of Open Medicine, a new medical education platform, and Dr. Rajkumar's ongoing advocacy on drug pricing reform.KEY TOPICS DISCUSSEDBaseline workup: 24-hour urine protein: It is important to obtain 24-hour urine protein with electrophoresis and immunofixation in all newly diagnosed patients — not for diagnosis, but to establish a baseline for long-term management and to distinguish M-protein from albuminuria. In patients where an FLC ratio ≥100 is the sole myeloma-defining criterion, a 24-hour urine Bence Jones protein ≥200 mg is part of the diagnostic threshold for treatment initiation. Myeloma cast nephropathy: when to biopsy: An involved FLC ≥50 mg/dL supports a presumptive diagnosis of cast nephropathy and treatment can begin without a kidney biopsy. Below this threshold — particularly if renal involvement is the sole myeloma-defining event — kidney biopsy is warranted to exclude light chain deposition disease, MPGN, or other unrelated disorders. It warrants aggressive early treatment (Dara-VCD or Dara-VD), starting even before bone marrow results are available when the diagnosis is clinically clear.Solitary plasmacytoma [with or without minimal bone marrow involvement]: Patients with ~10% clonal plasma cells technically meet criteria for myeloma, but management in this borderline zone warrants shared decision-making. Solitary plasmacytoma as sitting between smoldering myeloma and overt myeloma on the disease spectrum. Risk stratification: revised IMWG criteria: The new revision aimed to keep the high-risk designation to ≤15–20% of patients. Del 17p alone confers high-risk status. TP53 mutation without del 17p is exceedingly rare and FISH alone captures the vast majority of cases. All other cytogenetic abnormalities (t(4;14), t(14;16), t(14;20), 1q gain, 1p deletion, biallelic 1p) require at least one co-occurring abnormality to define high risk. Elevated β2-microglobulin with normal renal function is retained as a proxy for high tumor burden. Emergent indications for treatment initiation: The three situations warranting urgent treatment are acute cast nephropathy (days matter for renal recovery), cord compression (surgery vs. radiation vs. systemic therapy determined by acuity), and hypercalcemia. Induction regimen selection: For fit, transplant-eligible patients, the preferred induction is a quadruplet — Dara-VRd or Isa-VRd — with dose adjustment as needed. Triplets (Dara-Rd or Isa-Rd) are reserved for those unable to tolerate a quadruplet even with dose reduction. Carfilzomib-based induction is not favored: head-to-head data show no benefit of KRd over VRd in NDMM, and the cost differential is substantial. Lenalidomide dosing: Starting dose should be individualized: 15 mg for patients over 75, those with small body habitus (

Listen more about history of Manipur ,its culture, historical and integrated links with India, current political scenario, ground reality and way forward

April 29, 2026 ~ Attorney and political strategist Roshini Rajkumar breaks down the indictment tied to Dr. Fauci's former top advisor, unpacking the alleged COVID cover‑up and the political and legal fallout surrounding hidden emails. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

On MoneyFM 89.3’ Saturday Mornings Show host Glenn van Zutphen and co-host Neil Humphreys to talk to Chef Vicky Ratnani and Chef Raj Kumar about the lesser-know Sindi indian cuisine. A small sub-segment of "indian food" - Sindi came out of the partion of India and Pakistan. Recently for three nights in Singapore, Firangi Superstar restaurant hosted one of the most exciting culinary collaborations of the year brining Sindi cooking to town. Chef Vicky — one of India’s most celebrated chefs, former Executive Chef of the Queen Mary 2, TV personality, and award‑winning author — presented a deeply personal menu rooted in Sindhi cuisine, the food he grew up eating but rarely cooked professionally. Dishes like Sai Bhaji and Aloo Tukk Bravas showcased heritage elevated through modern technique. Chef Raj, Group Head Chef of The Dandy Collection, shares how Firangi Superstar is pushing Indian cuisine into new territory — bold, immersive, and unapologetically inventive. Together, they discuss the global rise of regional Indian cuisine, why Singapore is ready for this shift, and how events like the Sindhi Supper Club are rewriting expectations.See omnystudio.com/listener for privacy information.

April 24, 2026 ~ Attorney and political strategist Roshini Rajkumar reacts to Paige Shiver appearing on Good Morning America and the renewed attention surrounding Sherrone Moore. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Monty Pal: Hello everyone and welcome to the ASCO Daily News Podcast. I'm your host, Monty Pal. I'm a medical oncologist, underline medical oncologist, a professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. You're going to understand why I underlined "medical oncologist" there. I'm actually on the line today with two amazing hematologists. Today, we're going to actually explore treatments for high-risk smoldering multiple myeloma following the FDA's approval last year of daratumumab for the first-ever treatment of this indication. Now, this is based on the AQUILA trial, and this represents a huge shift in our traditional watch-and-wait approach to active disease interception. We're going to consider whether this landmark trial published in The New England Journal translates to day-to-day practice. I think it does, and we'll certainly make an argument for that. And I'm so fortunate today to have two internationally acclaimed experts here in the conversation: Dr. Vincent Rajkumar, senior author on the manuscript, and Dr. Saad Usmani, also an expert in his own right in myeloma. Dr. Rajkumar is the lead investigator of the AQUILA study. He's a professor of medicine and consultant in the divisions of hematology and hematopathology at the Mayo Clinic in Rochester, Minnesota. He actually chairs the Myeloma, Amyloidosis, Dysproteinemia Program. He is also editor-in-chief of the Blood Cancer Journal. Dr. Usmani, he and I actually go way, way back. We actually did the AACR Molecular Biology in Clinical Oncology course, I want to say in 2006, so this is our 20-year anniversary, Saad. He's the chief of the myeloma service at the MSK Cancer Center and a professor of medicine at the Weill Cornell Medical College in New York.  Saad, Vincent, welcome. Dr. Saad Usmani: Thank you so much for having me, Monty. Dr. Vincent Rajkumar: Yeah, thanks, Monty. A pleasure to be here. Dr. Monty Pal: Thanks. And just a quick note for our listeners, all of our disclosures are available in the transcript of this episode. First off, Saad, did I get that right? Was it 2006 when we did that course together? Dr. Saad Usmani: Yeah, 20 years. We are coming up to our 20-year anniversary. It's remarkable to have seen our careers move the way they have, Monty. Dr. Monty Pal: Oh my gosh. And for all the fellows who are on the line, that AACR Molecular Biology and Clinical Oncology course, it's sometimes overlooked. Wonderful primer on translational science. Okay, now we're going to get to the heart of the matter here, the AQUILA trial. So this was a study, Vincent, that you led. I wonder if you'd walk us through the primary endpoints in the study. What are we looking at in the AQUILA trial specifically? Dr. Vincent Rajkumar: Thanks so much. Again, as you mentioned, smoldering multiple myeloma has just been a condition that we watch and wait. And the first thing that I want to clarify here is that the AQUILA trial is looking at only a subset of smoldering multiple myeloma. That is the high-risk smoldering multiple myeloma. It was defined the way high-risk smoldering myeloma was defined at the time the trial was designed. It randomized 390 patients. One arm got daratumumab single agent in an attempt to delay progression to active myeloma and possibly prolong survival. And the other arm was the traditional observation. The primary endpoint, therefore, was time to active multiple myeloma. Other endpoints included time to when patients needed to start therapy for active multiple myeloma, which can vary based on physician judgment, and overall survival. Of course, response rate, complete response rate, and others were also endpoints. Dr. Monty Pal: That's interesting. And you know, I wanted you to riff a little bit on this definition of high-risk smoldering myeloma. Can you tell our audience how that's sort of evolved over the years? Dr. Vincent Rajkumar: Yes. I mean, if you step back, monoclonal gammopathy of undetermined significance has only a 1% per year risk of progression. Smoldering multiple myeloma, all comers have a 10% per year risk of progression. And over the years, trials have been done in the whole population, and then more recently, we felt we should really focus on the people with high-risk smoldering, defined as a 50-50 risk of progression in 2 years. That's like a 25% per year risk of progression in the first 2 years, which is a very high risk for the patient and something that would justify prophylactic intervention. And that definition initially was based on just high levels of monoclonal protein like more than 3 grams, the IgA subtype of myeloma, the suppression of uninvolved immunoglobulins. Others have used bone marrow flow cytometry markers, cytogenetics. Those combinations of factors were available at the time the AQUILA trial was designed, and a select combination was used. Later on, we found that we could match almost all of that in a very simple risk stratification using just the percentage of bone marrow plasma cells, the level of the M-spike, and the free light chain ratio, all three of which are available to all patients with smoldering at the time of diagnosis. So you don't need any special testing. So more than 20% plasma cells, more than 20 for the light chain ratio, and more than 2 grams for the M-spike. If someone has any two of the three, that is high-risk smoldering multiple myeloma according to the IMWG, but that definition, of course, came in 2020 after the AQUILA trial completed accrual. Dr. Monty Pal: That's interesting because this sort of flips the traditional paradigm where biomarkers get more and more complex as time goes on. Am I right in saying this sort of simplifies things a little bit? It uses standard laboratory or clinical parameters to gauge this category? Dr. Vincent Rajkumar: Absolutely. People were using suppression of uninvolved immunoglobulins, and those levels are not standardized, often vary by race. Also, the other aspect was the abnormal plasma cells on flow cytometry. Again, labs define it differently. So this makes it much more simple. But the IMWG also did a separate exploratory cohort within that paper where we added cytogenetics and we added scoring systems to improve on this further. So it simplified it for regular clinical practice and for like trials. But if you have a patient in front of you, the IMWG paper also has more complex scoring systems where you can take more than 20; 21 is more than 20, so is 51. And so, you can use the actual numbers that a patient has, additional variables like cytogenetics, and get a more refined estimate of what is the true risk of progression. Dr. Monty Pal: That's really helpful. Now, you told us about the primary endpoints, you've helped us define high-risk smoldering myeloma. Can you give us a sense of the top-line results from AQUILA? Dr. Vincent Rajkumar: Yes, I think the most important one was the primary endpoint, time to multiple myeloma, was at 5 years, the progression-free survival was 63% in the daratumumab arm compared to 41% in the observation arm. So, you know, approximately 60% of patients in the observation arm had already progressed by 5 years. And that number was about 40% for the daratumumab arm. We also looked at time to starting myeloma therapy, which is clinically actually quite meaningful because, you know, myeloma therapy means patients get a quadruplet for induction, they get stem cell transplant, they get endless maintenance, they get ongoing therapy virtually for the entire duration. So, preventing the need for myeloma therapy is in and of itself, I think, a major endpoint. And that at 3 years, 40% of people in the observation arm required full myeloma therapy compared to only 20% in the daratumumab arm. So there's a significant reduction in the risk of developing active myeloma as well as the need for myeloma therapy by using a time-limited 3 years of daratumumab single agent. Dr. Monty Pal: Perfect summary of the results. And maybe, Saad, I'm going to bring you into the conversation now. How does this sort of influence your day-to-day practice for smoldering myeloma? Is this something that you've incorporated for that high-risk subset? Dr. Saad Usmani: Thank you, Monty, and I agree. I think that's a really nice summary from Vincent. This study is very important for several reasons. It's actually the third clinical trial that has demonstrated that patients who are in the high-risk smoldering myeloma category benefit from an early intervention that delays the progression to active myeloma or to end-organ damage. And so having a nuanced discussion with our patients in the clinic becomes very important. Having this discussion around as an option becomes very important. And like Vincent said, when we look at that high-risk smoldering myeloma patient population, someone who has 22, 23% plasma cells versus, you know, 45, 50, you know, it's going to be a different discussion each time. But I think it's a very important first step. And I think this sets up the stage for us to design clinical trials where we can ask other questions on what would be better than daratumumab alone in terms of delaying progression in these patients. The other thing that I do want to highlight, and Vincent touched upon this a little bit, that the treatment in this clinical trial was for a fixed duration of treatment. So it was not forever treatment. This is maybe something that Vincent, you can even comment on a little bit more because the question we get after having this discussion is, "Okay, what do we do with patients who are going to be progressing to active myeloma?" Whether we can utilize anti-CD38 therapies for those. So Vincent, I would love your take on this too. Dr. Vincent Rajkumar: Yeah, I think, you know, the main philosophical change for me was previously, the thing was 'don't treat', and now for high-risk smoldering multiple myeloma, the question is, is daratumumab the best treatment or can we do something better? And those trials are thankfully ongoing. One of them has already completed accrual, isatuximab-len-dex versus len-dex. And another one is ongoing in ECOG, almost close to finishing accrual. And in the future, we'll be trying to see if we can use early intervention to even cure and prevent progression altogether.  So we are in this phase where we have one approved regimen, one approved drug, and we are not sure whether we can improve on that. The question is, "is a myeloma-like therapy better than monotherapy" would be the next question, and then what would we do further beyond that? In this context, whenever we have patients like this, one of the questions that comes up, as Saad mentioned, is how does this affect newly diagnosed myeloma therapy if somebody has been treated for smoldering and things like that? How will they be considered for clinical trials? Would they be considered as relapse myeloma or still newly diagnosed myeloma? And those are important discussions for clinical trialists to keep in mind, but I think for clinical practice, your duty is to the patient in front of you. If they have high-risk smoldering myeloma and there's data that there's treatments that can delay progression significantly, delay the need for myeloma therapy significantly, that's the highest priority. We'll cross that bridge.   There are so few patients going on clinical trials right now that if such a patient were to later on progress and wants to enter in a newly diagnosed myeloma trial later, years later, we can figure that out later. I feel like the most important discussion is what to do for that patient today. I still prefer a clinical trial if one was available. If one was not available, I'd prefer early intervention, but have an informed discussion with the patient because some of them may wish to delay therapy still. Some of them may have very borderline numbers that you want to watch them closely. Some of them may be having other comorbidities that prevent need for therapy. Some of them maybe have had the smoldering for a long time and you already know it's stable. So a lot of factors go in, and I think it's not a one-size-fits-all. Dr. Monty Pal: This is a terrific discussion, and you know, it sort of segues into maybe a question around biology. And this is something I was going to get to a little bit later, but Saad, I'm glad you brought it up. I'll liken it to the only thing I know, which is kidney cancer. So, you know, in kidney cancer, we use checkpoint inhibitors as adjuvant therapy. And there's this question of whether or not it breeds some resistance in the localized setting to ultimately what the patient might potentially be exposed to in the metastatic setting. Tell me your thoughts on this, Vincent, then maybe Saad separately. If you treat a patient with daratumumab in this high-risk smoldering setting, could it theoretically sort of limit options in the refractory setting now that we have regimens like DRBD that are kind of being utilized, or daratumumab with teclistamab? Vincent, I'll throw that to you first. Dr. Vincent Rajkumar: This is a great question, and it's usually asked when we've done the lenalidomide trials actually. We try to put the question back. If that was your concern, how would you actually solve it? Is it really biology that's going to answer that? Or is it a randomized trial? So the experiment has been done three times now where early intervention has been given. And if there was some detriment because of that, that would be reflected in the overall survival. In all three trials, there's no such detriment seen. In the first lenalidomide-dex trial, there was an improvement in overall survival. In the AQUILA trial again, the confidence interval doesn't cross one, and patients had better long-term survival on AQUILA, but certainly not less. We've also examined PFS2 data, and that doesn't seem to be affected. So yes, there is a theoretical concern, and that concern cannot be allayed for new treatments which we have not even tried, like tec-dara, and whether that effect would be there or not. But so far, I don't see it. And I think the onus is on proof of that in order to prevent people from getting early therapy. Dr. Monty Pal: Yeah. Saad, your thoughts on that? And before you jump in, I'll mention, we're kind of taking the same approach in kidney cancer, we're trying to really do studies to see whether or not, you know, immunotherapy rechallenge in these contexts, you know, really lends any substantial benefit. So far, the results have been interesting. I don't think we have enough numbers as yet to capture the impact of adjuvant therapy as it translates to metastatic, but I see so many similarities between the scenarios that you're facing in myeloma and what we're facing in RCC. Saad, your thoughts? Dr. Saad Usmani: Thanks, Monty. I'll go back to something that Vincent alluded to a few minutes ago about the way that we risk-stratify patients within smoldering myeloma. Right now, we are relying more on a disease burden-based stratification looking at the percentage of plasma cells in the bone marrow, the monoclonal protein, as well as the involved light chain versus the uninvolved light chain ratio. However, there are efforts underway to actually incorporate genomics into that schema and try to refine that definition of high-risk smoldering. And there have been two papers that came out in the latter half of last year. In fact. Dr. Rajkumar and I are co-senior authors on one effort where we can identify genomic myeloma in patients in precursor conditions. One of the key things that came out of that effort was that within the high-risk smoldering myeloma category, about 90% of the patients are genomically myeloma. So this whole debate of whether we need to intervene for those patients, I think, you know, we have sufficient biologic evidence that yes, we need to intervene for those patients.  I think that the next real step, like Vincent stated, is how do we intervene in those patients? And those clinical trials kind of are ongoing. We will probably need to have more validation of those genomic models being incorporated, but that's what I see in the future. I wouldn't be concerned for the patients being seen today with that query about the disease biology evolving because if I'm seeing a patient today in March of the first quarter of 2026 and offering them monotherapy daratumumab in their high-risk smoldering situation for the next 3 years and then they progress to myeloma after another couple of years, we are talking about what would be the treatment options for them in 2031, 2032. So I think the field is moving so fast, we have a lot of novel therapies coming into that frontline setting rapidly, so our options at that time would be very different. So, you know, I just wanted to kind of set up the stage for saying, you know, our tools are getting better in delineating which patients will need that intervention. And then eventually, I think, you know, we'll have much better options for newly diagnosed myeloma patients at the time when they need it in the future. Dr. Monty Pal: Just absolutely brilliant, absolutely brilliant. I love that summary. I think that you're absolutely right in saying that, you know, you've got to think about what you're going to do for that patient sort of in the moment, what's going to optimize their outcome and agree that the landscape is evolving very rapidly.  I'd be remiss, Saad, if I didn't ask you about something that I've been following in terms of your career trajectory. You've developed quite a reputation for your leadership in trials looking at CAR T-cell therapies for myeloma. Can you give us a sense of where that stands in broad terms? Dr. Saad Usmani: Certainly, Monty. I think the CAR Ts have slowly made their way from late relapse to early relapse. And now we have clinical trials that have completed accrual in the frontline setting comparing them to standard-of-care treatment for both older myeloma patients or transplant-ineligible patients, as well as younger transplant-eligible patients where we're actually trying to replace transplants with BCMA-directed CAR T-cell therapies. The nuance there would be we want to equal or better the survival outcomes that we've accomplished without compromising on the safety side of things for patients. Those therapies are moving into earlier lines. And more excitingly, you know, that's just the first wave of CARs. The next wave of CAR technology is coming, and it's going to be in vivo CARs where we may not need lymphodepleting chemotherapy, we may not even need as stringent regulatory nuances that we do for cellular therapies today. So, you know, I think the field is moving rapidly, and it's going to be a very interesting landscape to see over the next 5 to 6 years. Dr. Monty Pal: Yeah, you know, it's so interesting. I know in the solid tumor space, we're trying to replicate the success that you've had with CAR T and bispecifics, and I do see some light at the end of the tunnel. I'm seeing some really promising agents being developed, but clearly, we have so much to learn from our colleagues in hematology. Well, I have to tell you, this has just been a phenomenal conversation. Vincent, congratulations on your leadership of the AQUILA trial. Clearly, a big paradigm shift in the field. Saad, thank you for offering your expert insights and really giving us also a glimpse at the future of myeloma. Really appreciate having you both on the podcast today. Dr. Vincent Rajkumar: Thank you, Monty. Dr. Saad Usmani: Thank you so much. Dr. Monty Pal: And thank you so much to our listeners for your time today. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Monty Pal    @montypal   Dr. Vincent Rajkumar @VincentRK Dr. Saad Z. Usmani @szusmani   Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Vincent Rajkumar: Honoraria: Research to Practice, Medscape Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date Dr. Saad Usmani: Consulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, Abbvie, Bristol-Myers Squibb/Celgene, Regeneron, AstraZeneca, Sanofi Research Funding: Janssen Oncology, Bristol-Myers Squibb, K36 Therapeutics, Abbvie, Regeneron  

29.03.26//Palm Sunday_Matthew 21:1-17//Church Hill//Paul Rajkumar by Church Hill Anglican

In this episode, we sit down with Raj Kumar, former leader at Bharat Petroleum Corporation Limited (BPCL) and now founder of his own gas company, to unpack the real behaviours required to operate at CXO level. This isn't theory. This is lived experience from the energy sector — one of the most complex and high-pressure industries in the world. We cover: - The mindset shift from executive to owner - The behaviour required to lead at scale - Why strategy fails without discipline - Decision-making under pressure - Corporate leadership vs entrepreneurial leadership - What most professionals misunderstand about becoming a CXO Powered by Emeritus: www.emeritus.org #futureofwork #artificialintelligence #careergrowth #mindsetshift #reinventyourself #leadership #aijobs #careeradvice #personalgrowth #workplacetrends #mentalhealthatwork #resilience #lifelonglearning

Join us on this special episode of The Brand Called You as Aditi Kumar sits down with Pawan Raj Kumar, Partner at ZeCa Capital, entrepreneur, angel investor, and sustainability advocate.From scaling a family business internationally to mentoring over 100 entrepreneurs and building a sustainability-focused fund, Pawan shares insights into:Embracing challengesUnderstanding the role of luck and timingBuilding resilienceMeasuring success beyond moneyStaying endlessly curious

MONDAY MANNA - "Finish Well" (Bro. Stephen Rajkumar) - 16th February 2026

The path to a successful broadcast journalism career doesn't usually start in law school. But that's where Roshini Rajkumar, Boston College class of 1993, started hers. Rajkumar combined a genetic penchant for the cinematic arts with a passion for justice and sticking up for the little guy on her way through big city TV markets of the Midwest. And, then, twenty years ago this month, she turned entrepreneurial and launched a strategic consulting firm that would accompany her "The Crisis Files" podcast and legal analyst expertise. In episode 16 of Formative, we talk about how corporate brands can go awry when riffing on the news cycle; why objectivity ought not be a dirty word in journalism; and how the U.S. Constitution can offer the path out of the terrible crisis besieging her hometown of Minneapolis.

Raj Kumar, President and Editor-in-Chief of Devex, joins Justin Blake, Executive Director of the Edelman Trust Institute, for a recap of their time at the World Economic Forum Annual Meeting in Davos. Raj and Justin discuss the state of trust in NGOs, shifts in development finance, the impact of misinformation, and how AI could reshape the capacity to deliver in underserved communities.

In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of daratumumab for high-risk smoldering myeloma, based on the groundbreaking AQUILA study. We were joined by Dr. Vincent Rajkumar, a world-renowned myeloma specialist, who provided valuable insights into the complexities of smoldering myeloma, its risk stratification, and the implications of early intervention. Key topics discussed included: • The definition and classification of smoldering myeloma • The design and findings of the AQUILA trial • The significance of time to progression and overall survival in treatment • The risk-benefit analysis of daratumumab therapy, including potential side effects • Future directions in myeloma treatment and ongoing research Join us for an informative discussion as we bridge the gap between academic research and community practice, helping healthcare professionals and patients navigate the evolving landscape of myeloma treatment. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, conference highlights, and FDA approvals!

January 8, 2026 ~ Roshini Rajkumar, crisis strategist, licensed attorney, and host of The Crisis Files podcast joins Kevin to discuss the ongoing situation in Minneapolis Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Shikari Rajkumar - Premchand - Suno Kahani - शिकारी राजकुमार - प्रेमचंद - सुनो कहानी #premchand #premchandkikahani #premchandkikahaniyan #munshipremchand#munshipremchandkikahani #premchandkikahaniyan #hindikahaniyan #hindistories #kahani #kahaniyan #sunokahani #hindi #audiobook

This year countries grappled with a cascade of shocks and economic turbulence, from ongoing conflicts and economic uncertainty to catastrophic weather that tested communities. Yet in the face of these challenges, nations proved far more resilient and adaptive than predicted.In this episode of The Development Podcast, we look back at what shaped 2025 and look ahead to 2026 and beyond. As the global landscape rapidly shifts, we explore how Multilateral Development Banks (MDBs) are adapting and how different parts of the World Bank Group, including the International Finance Corporation (IFC) and the Multilateral Investment Guarantee Agency (MIGA), are working as one to maximize our development impact.Join us for insights on these issues and more from Anna Bjerde, the World Bank's Managing Director of Operations and Raj Kumar, the founding President and Editor-in-Chief of Devex.Timestamps[00:00] Challenges and takeaways from 2025[06:11] How development organizations are evolving and adapting[12:27] What can we expect from 2026?[16:26] Wish for the next year[17:30] 2025 through the eyes of a Kenyan farmerTo learn more about the World Bank Group's work check out: How to Drive Intelligent Outcomes in an Age of AI

After receiving a disappointing grade, Arjun Rajkumar changes his view on what perfection means.

What if you could know the true age of your brain—and start reversing it today?On this electrifying episode of Thrive LouD with Lou Diamond, recorded live at the Global Passion Project in Southampton, you'll get an insider's look at the breakthrough technologies—and bold thinkers—reshaping our future of health, longevity, and social impact.Lou sits down with a stellar lineup, including Dr. Ramses Alcaide, CEO of Neurable, who unveils how wearable brain-sensing headphones could soon make brain health measurements as common as step counters. Hear firsthand accounts from athletes concerned about cognitive decline, how new brain tech works for real users, and why investors like Peter Thiel, Chris Sacca, and Merck are betting big on brain longevity.Then, XPRIZE's Jason Bateman joins to pull back the curtain on the world's most audacious innovation prizes—from a $101M longevity award to wild carbon-capture ideas like artificial whale poop. Jason argues the biggest problems—like tribalism and the digital divide—need both competitive fire and courageous community to solve.The conversation turns to a dynamic panel with Dr. Jerome Corsi, Dr. Raj Kumar, Josh Rubin, and FDA legal expert Mike Druckman, who reveal how the pandemic, personal experience, and the hunger for systemic change are fueling a revolution in healthcare, data, and investment.If you're ready to meet the visionaries and game-changers shaping tomorrow—and learn what YOU can do about it—this is an episode you can't miss.Timestamped Overview:00:00 – Introduction Setting the scene for the Global Passion Project episodes01:01 – Dr. Ramses Alcaide shares how Neurable's brain-sensing technology is set to change healthcare (and everyday wearables)03:35 – Addressing privacy, safety, and real-world impact of brain data04:45 – Use case: Early detection of neurodegenerative conditions for athletes & those with family risks05:16 – Investors backing brain longevity and the growth of wearable brain tech06:15 – Partnering with the Department of Defense to protect soldiers' brain health07:27 – Scaling to military and commercial markets; 14 years of research brought to market 08:22 – What Dr. Ramses takes away from the Global Passion Project: Purpose, passion, and legacy09:09 – Where to find Neurable and connect with Dr. Ramses online09:50 – Jason Bateman of XPRIZE: Solving billion-scale challenges with multimillion-dollar prizes10:43 – Longevity, AI-driven education, space innovation, climate action, and wild ideas like artificial whale poop for carbon capture12:29 – The surprising origins of XPRIZE and how competition fuels innovation14:05 – Insights from the event: Harnessing capital, competition, and visionary philanthropy17:07 – Jason's biggest issue to solve: The digital divide and loss of empathy online18:50 – XPRIZE's next moonshots—like decoding the ovary's health signals21:49 – Jason's dream location: Bondi Beach, Australia22:30 – Panel intros: Dr. Jerome Corsi, Dr. Raj Kumar, Josh Rubin, and Mike Druckman reveal their personal missions and expertise26:43 – What's resonating at the event: Investment optimism and diverse passion for impact27:21 – Panel insights: Fusing expertise, diverse backgrounds, and hunger for change in healthcare28:20 – Dr. Raj's call to action: We need a little more anger and drive to change healthcare for all30:07 – Dr. Corsi: The role of global partnerships and funding to transform care30:56 – Panel contact details and their organizations for listeners and would-be collaborators34:27 – One-word summaries of the event: Inflection, Transformation, Loyalty, Spectacular 34:41 – Closing notes and where to connect with Thrive Loud and Lou Diamond

Dr. Rajkumar from the Mayo Clinic explains why many have been disappointed by the ODAC decision to recommend not approving Benrep for relapsed/refractory multiple myeloma. Thought provoking. This was taped live while we broadcasted on Twitter Spaces on 7/22/2025.

RJ Vaishnavi talks with director La. Rajkumar, the filmmaker behind Pettaikaali, Annanukku Jai, and Jallikattu. The discussion goes beyond films and into the qualities every new director should carry—especially the art of not judging by appearances. Just like a book isn't defined by its cover, or a video by its thumbnail, cinema too has deeper stories waiting to be discovered.

Raj Kumar, President and Editor-in-Chief of Devex, returns to High Impact Growth for a candid and insightful conversation about the future of global development. In a world reeling from sudden aid cuts and structural overhauls, Raj joins co-hosts Jonathan Jackson and Amie Vaccaro to unpack what this era of uncertainty means for NGOs, governments, and social enterprises alike.They explore:- The fallout from peak Official Development Assistance (ODA) and what it means for program funding- Why value-for-money is now a survival imperative, not a nice-to-have- How social enterprises can adapt to a world led by MDBs, DFIs, and outcome-based models.- The future of localizationThis episode is a must-listen for anyone navigating the evolving landscape of development funding — from social entrepreneurs and INGO leaders to funders and policymakers. Don't miss Raj's sharp insights on what needs to change and how organizations can shape the future before it hardens.

Raj Kumar Singh is a PhD researcher in Anthropology at the University of Delhi, currently studying the relationship between religion and economy in Mcleodganj, Dharamshala. He has published several articles and book chapters on Hindu nationalism, Tibetan Buddhism, and the relationship between Communism, Buddhism, and Dr. Babasaheb Ambedkar. Visit Sacred Writes: https://www.sacred-writes.org/2025-carpenter-cohorts-summer  

Abby and Patrick are joined by somatics practitioner Sumitra Rajkumar to clarify the theory and practice of somatics and its relationship to ideas of personal and collective transformation. Sumitra walks Abby and Patrick through somatics as a theoretical perspective that sees the self as both thoroughly grounded in our individual bodies but also always bound up in relational, social bodies as well. She unpacks how somatic practice differs from talk therapy by using techniques of “bodywork” and other exercises to explore histories of “shaping,” undo habitual patterns of embodiment, address trauma, and cultivate a capacity to remain centered and present under pressure. As the three explore, what sets Sumitra's approach apart from ostensibly “apolitical” or openly right-wing traditions is a self-conscious, critical awareness of power dynamics and different people's varied relationships to historical oppression and their own bodies. Over and against “apolitical,” mystical, or openly right-wing tendencies of other practices, Sumitra's vision of somatics is particularly attuned to the physical and psychic tolls of maintaining compassion, resisting burnout, and building relationships of solidarity with strangers. Rich with psychoanalytic resonances throughout, their conversation focuses in particular on the concept of the “transferential constellation,” which clarifies a great deal about the different dynamics between right and left mass movements, and casts many difficult experiences – whether in a consulting room, at a protest, or canvassing by knocking on doors – in provocative new light.The Action Lab: https://www.actionlabny.org/Art of Purpose fellowship application: https://www.canva.com/design/DAGsmA_TIm0/7-aSlMVivPoR4kHvJD-Hbg/view?utm_content=DAGsmA_TIm0&utm_campaign=designshare&utm_medium=link2&utm_source=uniquelinks&utlId=h12e5faa7a3#1More on somatics and Sumitra's work:What is somatics? Somatics in practiceInstitutions Sumitra mentions include:Generative Somatics: https://generativesomatics.org/BOLD: https://www.boldorganizing.org/The Embodiment Institute: https://www.theembodimentinstitute.org/The Organizing Center: https://www.theorganizingcenter.org/The tweet that started this conversationHave you noticed that Freud is back? Got questions about psychoanalysis? Or maybe you've traversed the fantasy and lived to tell the tale? Leave us a voicemail! (646) 450-0847A podcast about psychoanalysis, politics, pop culture, and the ways we suffer now. New episodes on Saturdays. Follow us on social media:Linktree: https://linktr.ee/OrdinaryUnhappinessTwitter: @UnhappinessPodInstagram: @OrdinaryUnhappinessPatreon: patreon.com/OrdinaryUnhappinessTheme song:Formal Chicken - Gnossienne No. 1https://open.spotify.com/album/2MIIYnbyLqriV3vrpUTxxOProvided by Fruits Music

June 17, 2025 ~ Roshini Rajkumar joins Kevin to discuss how Minnesota is reacting to the lawmaker shooting.

A federal judge has ordered the Trump administration to release hundreds of millions of dollars in housing and transit funds it was withholding from New York City. Meanwhile, the two leading Democratic candidates for public advocate, Jumaane Williams and Jenifer Rajkumar, traded sharp attacks in their first televised debate. Also, the New York Liberty have opened the season with eight straight wins, their best start in franchise history. Plus, in this week's transit segment: a new 15 mph speed limit for e-bikes, bus-only lanes coming to Flatbush Avenue, and Amtrak proposes direct service to Long Island for the first time.

Send us a text Kathy, Mark and Burk react to the Teaser for RAID 2, an upcoming Indian Hindi-language crime thriller film directed by Raj Kumar Gupta. It stars Ajay Devgn, Riteish Deshmukh and Vaani Kapoor. A sequel to Raid (2018), Raid 2 follows the return of IRS officer Amay Patnaik who tracks another white-collar crime.Support the show

Explosive growth in the middle class, rapid urbanization, digitization and automation, the energy transition, and evolving geopolitics — these all present unique challenges for today's businesses, said Jonathan Fantini-Porter, senior vice president of social impact in the Americas at Mastercard Center for Inclusive Growth. It's against this backdrop that public and private sector leaders are grappling with questions of longevity, opportunity, and continued growth. With this in mind, Mastercard Center for Inclusive Growth and Devex convened over 400 practitioners from the fields of tech, policy, and finance last month in Washington, D.C., for the Global Inclusive Growth Summit. The sessions and conversation centered on what it takes to create and lead economic growth, how to future-proof an organization's mission, and the role of innovative leadership in shaping a better future. “The key is the shared urgency around how we future-proof inclusive growth … and the importance of cross-sector collaboration at scale,” said Fantini-Porter. “Siloed solutions just aren't enough in this context that we're living through at this point.” Taking that conversation beyond the summit, Fantini-Porter talks to Raj Kumar, Devex's president and editor-in-chief, in a special podcast episode about how businesses — especially small businesses in rural areas — can create resilience in their communities and support economic opportunities for all. This special episode of This week in Global Development was sponsored by the Mastercard Center for Inclusive Growth.

Summary Garance Wattez-Richard, CEO of AXA EssentiALL, discusses the transformative potential of inclusive insurance in addressing vulnerabilities, particularly in low and middle-income countries. She sits down with Raj Kumar to share her journey into the insurance industry, the evolution of microinsurance, and the importance of regulatory frameworks. The discussion highlights the profitability of inclusive insurance and its critical role in achieving sustainable development goals, especially in the context of climate change. Chapters 00:00 The Risk of Vulnerability 00:47 Revolutionizing Insurance for All 01:37 A Journey into Development and Insurance 06:45 The Evolution of Microinsurance 11:41 Profitability in Inclusive Insurance 14:50 The Risks of Insurance Solutions 19:15 Regulatory Challenges in Emerging Markets 23:07 Insurance as a Core Development Activity 28:13 The Future of Insurance and Development Want to stay updated on the latest news in global development? Subscribe to Devex's Newswire: https://www.devex.com/newsletters/newswire 

SummaryGarance Wattez-Richard, CEO of AXA EssentiALL, discusses the transformative potential of inclusive insurance in addressing vulnerabilities, particularly in low and middle-income countries. She sits down with Raj Kumar to share her journey into the insurance industry, the evolution of microinsurance, and the importance of regulatory frameworks. The discussion highlights the profitability of inclusive insurance and its critical role in achieving sustainable development goals, especially in the context of climate change. Chapters00:00 The Risk of Vulnerability00:47 Revolutionizing Insurance for All01:37 A Journey into Development and Insurance06:45 The Evolution of Microinsurance11:41 Profitability in Inclusive Insurance14:50 The Risks of Insurance Solutions19:15 Regulatory Challenges in Emerging Markets23:07 Insurance as a Core Development Activity28:13 The Future of Insurance and Development Want to stay updated on the latest news in global development? Subscribe to Devex's Newswire: https://www.devex.com/newsletters/newswire 

Summary Discover why "business as usual" fails in the world's toughest places. Viva Ona Bartkus sits down with Raj Kumar to reveal the counterintuitive tactics that unlock massive opportunities where others fear to tread. Learn why: The most successful security strategy isn't higher walls – it's community ownership How to turn "middlemen with guns" into business partners Why Chinese companies are winning while Western firms hesitate Plus: The radical partnership model that's transforming dangerous markets from Uganda to Colombia. Bartkus shares explosive insights from 15+ years working with multinationals, Special Forces, and local communities in conflict zones. – Chapters 00:00 Embedding Business in Local Communities 01:53 The Journey to Frontline Markets 07:02 Understanding Market Dynamics 11:18 The Role of Middlemen in Local Economies 12:45 Security Through Community Engagement 16:14 The Next Round of Globalization 20:02 The Competitive Landscape of Global Investment 23:42 Collaboration Between Security and Development 25:28 Bridging the Gap Between Business and Humanitarian Efforts 28:41 The Role of ESG in Business Strategies 31:17 Adapting Business Models for Extractive Industries 36:43 The Future of Development Finance – Want to stay updated on the latest news in global development? Subscribe to Devex's Newswire: https://www.devex.com/newsletters/newswire

SummaryDiscover why "business as usual" fails in the world's toughest places. Viva Ona Bartkus sits down with Raj Kumar to reveal the counterintuitive tactics that unlock massive opportunities where others fear to tread. Learn why:The most successful security strategy isn't higher walls – it's community ownershipHow to turn "middlemen with guns" into business partnersWhy Chinese companies are winning while Western firms hesitatePlus: The radical partnership model that's transforming dangerous markets from Uganda to Colombia. Bartkus shares explosive insights from 15+ years working with multinationals, Special Forces, and local communities in conflict zones.Chapters00:00 Embedding Business in Local Communities01:53 The Journey to Frontline Markets07:02 Understanding Market Dynamics11:18 The Role of Middlemen in Local Economies12:45 Security Through Community Engagement16:14 The Next Round of Globalization20:02 The Competitive Landscape of Global Investment23:42 Collaboration Between Security and Development25:28 Bridging the Gap Between Business and Humanitarian Efforts28:41 The Role of ESG in Business Strategies31:17 Adapting Business Models for Extractive Industries36:43 The Future of Development FinanceWant to stay updated on the latest news in global development? Subscribe to Devex's Newswire: https://www.devex.com/newsletters/newswire 

On this show we will explore the ending of foreign aid from the American government USAID and its horrendous ramifications. Our guest Raj Kumar is a Washington, D.C.-based social impact leader, journalist, and author specialized in global development. He is the President & Editor-in-Chief of Devex, the independent news organization, and the author of The Business of Changing the World, an influential book about the future of global aid and philanthropy.

Why should we take the gospel to the college campus? Apollo Rajkumar reminds us of God's calling on our global family of churches to preach the gospel and make disciples on campus. Apollo is a Pastor and Church Planter at Every Nation India in Pune, India.

Returning to the show, Drs. Vincent Rajkumar and Aaron Goodman engage in a dynamic debate over the evolving landscape of smoldering multiple myeloma, focusing on the highly anticipated study recently co-authored by Dr. Rajkumar and published in The New England Journal of Medicine after being presented at ASH 2024. They dissect the study's findings, which highlight the impact of early intervention with daratumumab in delaying disease progression for patients classified as high-risk. The discussion explores the nuances of smoldering myeloma classification, the controversy surrounding risk stratification, and the historical context of prior studies that failed to change clinical practice. With their expert insights, Drs. Rajkumar and Goodman break down the implications of this research, questioning whether it truly shifts the standard of care and what it means for future treatment approaches. View the NEJM publication. https://www.nejm.org/doi/abs/10.1056/NEJMoa2409029 Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

We are so honored to welcome back Dr. S. Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He is also Editor-In-Chief of Blood Cancer Journal and the Chairperson of the Board of the International Myeloma Foundation. This week's episode will be focusing on additional pearls for the treatment of Multiple Myeloma including options for refractory disease, as well as advice for trainees.

We are so honored to welcome Dr. S. Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He is also Editor-In-Chief of Blood Cancer Journal and the Chairperson of the Board of the International Myeloma Foundation. This week's episode will be focusing on Multiple Myeloma symptoms, diagnostic criteria, work-up and initial treatment.

Special Olympics' Chief of Global Youth & Education, Jackie Jodl, joins Raj Kumar for a podcast episode looking at how sports and education can drive societal change, the state of social inclusion for people with intellectual and learning disabilities, and the opportunities and risks presented by AI. This episode is sponsored by Special Olympics.

What moves us to preach the gospel to others? Apollo Raj Kumar reveals God's heart for the lost and what purpose that gives the Church.Apollo is a Pastor and Church Planter at Every Nation India in Pune, India.

Howie and Harlan are joined by Rahul Rajkumar, founder and CEO of Accompany Health, which provides a team of providers for patients who are on both Medicare and Medicaid. Harlan reflects on a visit to China and the healthcare ramifications of proposed legislation that would force U.S. biotech companies to cut ties with some Chinese partners. Howie provides an update on healthcare-related measures on state ballots in last week's election.  Links: China and the Biosecure Act “Congress takes up a series of bills targeting China, from drones to drugs” “U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners” Accompany Health Accompany Health Medicare: Dual-Eligibles Centers for Medicare & Medicaid Services: Dual Eligible Special Needs Plans “Medicaid Enrollees by Enrollment Group” “Justice Department sues to block UnitedHealth Group's $3.3 billion purchase of Amedisys” “10 Reasons Why Medicare Advantage Enrollment is Growing and Why It Matters” Healthcare on the Ballot “7 states vote to protect abortion rights, while efforts to expand access in Florida, Nebraska and South Dakota fail” “Marijuana and Drug Policy on the Ballot” “Massachusetts voters reject proposal to legalize certain psychedelic drugs” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

The International Monetary Fund-World Bank Group 2024 Annual Meetings marked a turn of the page to the next phase of our mission: Ensuring job creation—and employment—are not the byproduct of our projects but an explicit aim of them. In this latest episode of The Development Podcast, we draw on some of the highlights from the Annual Meetings, as well as announcements on creating a new eco-system for agribusiness and boosting economic opportunities for more women. We hear from Ajay Banga, President of the World Bank Group; Situmbeko Musokotwane, Minister of Finance for Zambia; Mabouba Diagne, Minister for Agriculture, Food and Livestock in Senegal; Ndidi Okonkwo Nwuneli, President and CEO of the ONE Campaign; Sandra Ablamba Johnson, Minister and Secretary General at the Presidency of Togo; Adebayo Olawale Edun, Nigeria's Minister of Finance; and Raj Kumar, President & Editor-in-Chief at Devex. Timestamps[00:00] Welcome and introduction of the topic[01:33] World Bank's evolution process towards a bigger, better Bank[04:35] Agriculture and food as an engine of sustainable growth and jobs[08:17] Accelerating women's economic opportunities[11:58] Jobs creation, International Development Association, World Bank Group scorecard[15:03] IDA21 replenishment[17:51] Highlights and announcements[21:04] Cooperation between the Global North and the Global South[23:03] Climate change and COP29ABOUT THE DEVELOPMENT PODCASTThis international development podcast brings together the data, research—and solutions—that can pave the way to a sustainable future. Through conversations focused on revealing the latest data, the best research, and cutting-edge solutions, let us introduce you to the folks working to make the world a better place. Listen and subscribe for free on your favorite platform. And rate our show! ;) Tell us what you think of our podcast here >>>. We would love to hear from you! ABOUT THE WORLD BANKThe World Bank is one of the world's largest sources of funding and knowledge for low-income countries. Its five institutions share a commitment to reducing poverty, increasing shared prosperity, and promoting sustainable development.

In this episode, Rajkumar Venkatramani shares his journey from being a physician to becoming a multifamily real estate investor. He discusses the current challenges in the market, including investor skepticism and rising expenses, and how his investment strategy has evolved over the years. Raj highlights the importance of patience in partnerships and the critical role of pricing in real estate investments, especially when analyzing distressed properties. Rajkumar Venkatramani | Real Estate Background REIDOC Capital Portfolio: 2000+ Multifamily Units Based in: Houston, TX Say hi to him at: LinkedIn www.reidoccapital.com Sponsors: Altra Running

Recently released on bail, a middle-aged man returns to a home he's been ordered to stay away from and allegedly attacks. After a miraculous recovery, a traumatized teenage girl and her mother are left with the same question as police and their community, where is Harry Rajkumar? For more info, please go to https://globalnews.ca/tag/crime-beat/ Subscribe to Crime Beat TV HERE:    / crimebeattv   Like Global News on Facebook HERE: http://bit.ly/255GMJQ Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB #GlobalNews #CrimeBeat Learn more about your ad choices. Visit megaphone.fm/adchoices

Surgical clearance, NICM assessment, dueling perspectives on PCI as first-line therapy for angina, GDMT in HFrEF are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. New ACC Peri-operative Guidelines Released ACC Guideline document https://www.jacc.org/doi/10.1016/j.jacc.2024.06.013 J Vasc Surg https://www.jvascsurg.org/article/S0741-5214(21)00335-9/fulltext McFalls and colleagues; CARP https://www.nejm.org/doi/full/10.1056/NEJMoa041905 II. NICM – We may be doing it wrong in Selecting ICDs JAMA Meta-analysis https://jamanetwork.com/journals/jama/fullarticle/2823869/ German CMR ICD Trial https://www.clinicaltrials.gov/study/NCT04558723 BRITISH CMR trial https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/britishusing-cmr-scar-as-risk-indication-tool-in-nicm-and-severe-lvsd/ III. When Should PCI be Used in Chronic Stable CAD?   Rajkumar and Al-Lamee; PCI First https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011201   Boden and De Caterina; Meds First https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011268 ORBITA 10.1016/S0140-6736(17)32714-9 ORBITA 2 trial https://www.nejm.org/doi/full/10.1056/NEJMoa2310610 IV. GDMT Underuse in HFrEF Greene and colleagues https://doi.org/10.1016/j.jchf.2024.08.002 DAPA HF https://www.nejm.org/doi/full/10.1056/NEJMoa1911303 RALES https://www.nejm.org/doi/full/10.1056/NEJM199909023411001 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Send us a textPepe Trailer Reaction!  @D54pod   Kannada | Vinay Rajkumar | Shreelesh SNair! Kathy and Amit react to the blood-soaked trailer for Pepe, a Kannada thriller starring Vinay Rajkumar. Written andDirected by Shreelesh s Nair, Bankrolled by Uday Cine Venture & Deepa Films #pepethefilm #vinayrajkumar #KaajalKunderMovie Details:Cast : Vinay Rajkumar , Mayur Patel , Naveen D Padil , Yash Shetty , Kaajal Kunder , MediniKelamane , Raviprasad Mandya , Kitty Sridhar , Shashidhar Bhat , Bala Rajwadi , Aruna Balraj ,Sandya Arekere , Shivu KabbanahalliProduction Banner : Uday Cine Venture - Deepa FilmsProduced by : Uday Shankar S - B.M. Sriram KolarWriter & Director : Shreelesh S NairMusic Director : Poornachandra TejaswiSingers : JG Kumara, Girijana Samagra Abhivruddhi Kala SamstheLyricist : JB Ramesha & Team Girijana Samagra Abhivruddhi Kala SamstheAudio Label : P R K AudioCinematography : Abhishek G KasaragodAdditional Cinematographer : Manprasad - Samarth Upadya - Rohit Kumar Padmanabha -S.Naveen Kumar - Karan Prasad - Abin Rajesh, Chanthu Meppayur - Akhil Thomas VargheseEditor : Manu ShedgarLyrical Video : Prashanth R.BStunts : Dr. K.Ravivarma - Chetan D'Souza - Different Danny - NarasimhaArt : Raghu MysureAudiography : Rahul RajanDI Colourist : Tom C Jose - DhanushVFX Supervisor : Akshay Kumar GCashier : Gopi G GowdaSound Design : Ravi HiremathDirection Department : Prashanth Basavaraj - Lokesh Rangaswamy - Raghavendra Arav -Dakshinamurthy H.R - Prasanna KumarStill : Akhil - PraveenPost Production : Studio 32PRO : Harish ArasTeam PRK Audio : Satish V*Get early access to these reviews by joining Patreon or our YouTube channel! YouTube Membershiphttps://www.youtube.com/channel/UCvt8UhKoTahIIRGIwxzUVVA/joinPatreonhttps://www.patreon.com/CinemondoPodcastJoin this channel to get access to fun perks like exclusive content and private Discord channel!:https://www.youtube.com/channel/UCvt8UhKoTahIIRGIwxzUVVA/joinOfficial Swag https://shop.spreadshirt.com/cinemondoNew videos daily!!Subscribe for the latest movie reviewshttps://www.youtube.com/channel/UCvt8UhKoTahIIRGIwxzUVVA?sub_confirmation=1

Crisis Files founder & star Roshini Rajkumar joins Dawn & Jim & shares tips on handling crisis & how it affects sports. Plus Vikings, Twins, Lynx, & Maya Moore.   Thanks to Rudy Luther Toyota (https://www.rudyluthertoyota.com/) & Minnesota Masonic Charities (https://mnmasoniccharities.org/)